New Study Finds Omicron Boosters Aren't Showing Any Benefit Over Previous Shots—But 20 Million Americans Already Received It

The bivalent vaccine is said to target two strains of the coronavirus, including Omicron. On October 13, 2022, Pfizer claimed they had "positive early data" from clinical trials, suggesting that the bivalent booster is "anticipated to provide better protection" against the Omicron variant. However, a recent study conducted by researchers at the University of Michigan and Columbia University found that the Omicron-specific booster failed to induce antibodies in participants who received Moderna's or Pfizer's bivalent vaccine. Apparently, the current boosters aren’t showing any benefits over the previous jabs. After three to five weeks of recipients receiving the booster, the vaccine was found to have “similar neutralizing antibody titers as those receiving a fourth monovalent mRNA vaccine.”